Metabolism of 1-methyl-4-phenyl-1,2,3/6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6 implications in parkinson disease

Journal of Biological Chemistry

Volumn 288, Issue 6, 2013, Pages 4436-4451

  Bajpai, Prachi ^a   Sangar, Michelle C ^a   Singh, Shilpee ^a   Tang, Weigang ^a   Bansal, Seema ^a   Chowdhury, Goutam ^b   Cheng, Qian ^b   Fang, Ji Kang ^a   Martin, Martha V ^b   Guengerich, F Peter ^b   Avadhani, Narayan G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1-METHYL-4-PHENYLPYRIDINIUM; ADRENODOXIN; CHEMICAL SYNTHESIS; COMPLEX I; CYTOCHROME P450; DEPRENYL; DOPAMINERGIC NEURONS; GLIAL CELLS; HUMAN CYTOCHROME; MITOCHONDRIAL TRANSLOCATION; MONOAMINE OXIDASE B; NEURO-2A CELLS; NEURONAL DAMAGE; NEURONAL DEATH; OPIOID ANALGESICS; OUTER MEMBRANE; PARKINSON DISEASE; PURIFIED ENZYME; REACTIVE OXYGEN SPECIES; SIDE PRODUCTS;

CELL MEMBRANES; CYTOLOGY; DISEASES; METABOLISM; PHYSIOLOGY;

NEURONS;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADRENODOXIN; CYTOCHROME P450 2D6; FERREDOXIN NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE REDUCTASE; MONOAMINE OXIDASE B INHIBITOR; PARGYLINE; PARKIN; QUINIDINE; REACTIVE OXYGEN METABOLITE; SELEGILINE;

ANIMAL CELL; ARTICLE; AUTOPHAGY; CATALYSIS; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; ENZYME PURIFICATION; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SYNTHESIS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CELL LINE; CYTOCHROME P-450 CYP2D6; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; DYNAMINS; HUMANS; MICE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; PARKINSONIAN DISORDERS; QUINIDINE; REACTIVE OXYGEN SPECIES; UBIQUITIN-PROTEIN LIGASES;

EID: 84873676565     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.402123     Document Type: Article

References (68)

1. Kopin, I. J., and Markey, S. P. (1988) MPTP toxicity. Implications for research in Parkinson disease. Annu. Rev. Neurosci. 11, 81-96
2. Meredith, G. E., Sonsalla, P. K., and Chesselet, M. F. (2008) Animal models of Parkinson disease progression. Acta Neuropathol. 115, 385-398
3. Sonsalla, P.K., and Heikkila, R. E. (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129, 339-345
4. Chiba, K., Trevor, A., and Castagnoli, N, Jr. (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574-578
5. Chiba, K., Peterson, L. A., Castagnoli, K. P., Trevor, A. J., and Castagnoli, N., Jr. (1985) Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyri-dine. DrugMetab. Dispos. 13, 342-347
6. Przedborski, S., Tieu, K., Perier, C, and Vila, M. (2004) MPTP as a mitochondrial neurotoxic model of Parkinson disease. J. Bioenerg. Biomembr. 36, 375-379
7. Bezard, E., Gross, C. E., Fournier, M. C, Dovero, S., Bloch, B., and Jaber, M. (1999) Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155, 268-273
8. Ramsay, R. R., Dadgar, J., Trevor, A., and Singer, T. P. (1986) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39, 581-588
9. +, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch. Biochem. Biophys. 259, 645-649
10. +) cause rapid ATP depletion in isolated hepa-tocytes. Biochem. Biophys. Res. Commun. 137, 310-315
11. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170, 1049-1055
12. Rossetti, Z. L., Sotgiu, A., Sharp, D. E., Hadjiconstantinou, M., and Neff N. H. (1988) 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37, 4573-4574
13. Bloem, B.R., Irwin, I., Buruma, O.J., Haan, J., Roos, R. A., Tetrud, J.W., and Langston, J. W. (1990) The MPTP model. Versatile contributions to the treatment of idiopathic Parkinson disease. J. Neurol. Sci. 97, 273-293
14. Siegle, I., Fritz, P., Eckhardt, K., Zanger, U. M., and Eichelbaum, M. (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11, 237-245
15. Coleman, T., Ellis, S. W., Martin, I. J., Lennard, M. S., and Tucker, G. T. (1996) 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) is N-dem-ethylated by cytochromes P450 2D6, 1A2, and 3A4-implications for susceptibility to Parkinson disease. J. Pharmacol. Exp. Ther. 277, 685-690
16. Gilham, D. E., Cairns, W., Paine, M. J., Modi, S., Poulsom, R., Roberts, G. C, and Wolf, C. R. (1997) Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human fetal and adult brain by in situ hybridization. Xenobiotica 27, 111-125
17. Hanna, I. H, Kim, M. S., and Guengerich, F. P. (2001) Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Arch. Biochem. Biophys. 393, 255-261
18. Herraiz, T., Guillén, H, Arán, V. J., Idle, J. R., and Gonzalez, F. J. (2006) Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated β-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol. Appl. Pharmacol. 216, 387-398
19. Modi, S., Gilham, D. E., Sutcliffe, M. J., Lian, L. Y., Primrose, W. U., Wolf C. R., and Roberts, G. C (1997) N-Methyl-4-phenyl-1, 2, 3, 6-tetrahydro-pyridine as a substrate of cytochrome P450 2D6. Allosteric effects of NA-DPH-cytochrome P450 reductase. Biochemistry 36, 4461-4470
20. Narimatsu, S., Tachibana, M., Masubuchi, Y., and Suzuki, T. (1996) Mutant debrisoquine hydroxylation genes in Parkinson disease. Chem. Res. Toxicol. 9, 93-98
21. Gołab-Janowska, M., Honczarenko, K., Gawrońska-Szklarz, B., and Po-temkowski, A. (2007) A CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia. Neurol. Neurochir. Pol. 41, 113-121
22. Smith, C. A., Gough, A. C, Leigh, P. N, Summers, B. A., Harding, A. E., Maraganore, D. M., Sturman, S. G., Schapira, A. H, Williams, A. C, and Maranganore, D. M. (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson disease. Lancet 339, 1375-1377
23. Halling, J., Petersen, M. S., Grandjean, P., Weihe, P., and Brosen, K. (2008) Genetic predisposition to Parkinson disease. CYP2D6 and HFE in the Faroe Islands. Pharmacogenet. Genomics 18, 209-212
24. Kallio, J., Marttila, R. J., Rinne, U. K., Sonninen, V., and Syvälahti, E. (1991) Debrisoquine oxidation in Parkinson disease. Acta Neurol. Scand. 83, 194-197
25. Persad, A. S., Stedeford, T., Tanaka, S., Chen, L., and Banasik, M. (2003) Parkinson disease and CYP2D6 polymorphism in Asian populations. A meta-analysis. Neuroepidemiology 22, 357-361
26. Sangar, M. C, Anandatheerthavarada, H. K., Tang, W., Prabu, S. K., Martin, M. V., Dostalek, M., Guengerich, F. P., and Avadhani, N. G. (2009) Human liver mitochondrial cytochrome P450 2D6 -individual variations and implications in drug metabolism. FEBSJ. 276, 3440-3453
27. Sangar, M. C, Bansal, S., and Avadhani, N. G. (2010) Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. Expert Opin. DrugMetab. Toxicol. 6, 1231-1251
28. Dutheil, F., Dauchy, S., Diry, M., Sazdovitch, V., Cloarec, O., Mellottée, L., Bièche, I., Ingelman-Sundberg, M., Flinois, J. P., de Waziers, I., Beaune, P., Declèves, X., Duyckaerts, C, and Loriot, M. A. (2009) Xenobiotic metabolizing enzymes and transporters in the normal human brain. Regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab. Dispos. 37, 1528-1538
29. Morgenstern, J. P., and Land, H. (1991) Choice and manipulation of retroviral vectors. Methods Mol. Biol. 7, 181-206
30. Krajl, M. (1965) A rapid microfluorimetric determination of monoamine oxidase. Biochem. Pharmacol. 14, 1684-1686
31. Lowry, O. H, Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275
32. Wu, M., Neilson, A., Swift, A. L., Moran, R., Tamagnine, J., Parslow, D., Armistead, S., Lemire, K., Orrell, J., Teich, J., Chomicz, S., and Ferrick, D. A. (2007) Multiparameter metabolic analysis reveals a close link be tween attenuated mitochondrial bioenergetic function and enhanced gly colysis dependency in human tumor cells. Am. J. Physiol. Cell Physiol. 292, C125-C136
33. Birch-Machin, M. A., and Turnbull, D. M. (2001) Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol. 65, 97-117
34. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr. Purif. 24, 329-337
35. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378
36. Guengerich, F. P. (1982) in Principles and Methods of Toxicology (Hayes, A. W., ed) pp. 609-634, Raven Press, Ltd., New York
37. Sangar, M. C., Anandatheerthavarada, H. K., Martin, M. V., Guengerich, F. P., and Avadhani, N. G. (2010) Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting. Mol. Genet. Metab. 99, 90-97
38. Grace, J. M., Kinter, M. T., and Macdonald, T. L. (1994) Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N, a-dimethyl-N-propynyl- phenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 7, 286-290
39. Mizuno, Y., Suzuki, K., Sone, N, and Saitoh, T. (1988) Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci. Lett. 91, 349-353
40. Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., and Guo, M. (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162-1166
41. Murphy, A. N. (2009) In a flurry of PINK, mitochondrial bioenergetics takes a leading role in Parkinson disease. EMBO Mol. Med. 1, 81-84
42. Arnoult, D. (2007) Mitochondrial fragmentation in apoptosis. Trends Cell Biol. 17, 6-12
43. Kohutnicka, M., Lewandowska, E., Kurkowska-Jastrzebska, I., Członkowski, A., and Członkowska, A. (1998) Microglial and astrocytic involvement in a murine model of Parkinson disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Immunopharmacology 39, 167-180
44. Molyneaux, B. J., Arlotta, P., Menezes, J. R., and Macklis, J. D. (2007) Neuronal subtype specification in the cerebral cortex. Nat Rev. Neurosci. 8, 427-437
45. Robertson, D. C, Schmidt, O., Ninkina, N, Jones, P. A., Sharkey, J., and Buchman, V. L. (2004). Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of 7-sy-nuclein, a-synuclein, and double a/7-synuclein null mutant mice. J. Neu-rochem. 89, 1126-1136
46. Bach, M. V., Coutts, R. T., and Baker, G. B. (2000) Metabolism of N, N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line. Xenobiotica 30, 297-306
47. Dragoni, S., Bellik, L., Frosini, M., Sgaragli, G., Marini, S., Gervasi, P. G., and Valoti, M. (2003) L-Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes. Xenobiotica 33, 181-195
48. Rittenbach, K. A., and Baker, G. B. (2007) Involvement of cytochromes P450 2D6, 2B6, and 2C19 in the metabolism of (-)-deprenyl and N-meth-yl, N-propargylphenylethylamine. Drug Metab. Lett. 1, 97-100
49. Dyck, L. E., and Davis, B. A. (2001) Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine andbyN-(2-heptyl)-propargylamine. DrugMetab. Dispos. 29, 1156-1161
50. Sharma, U., Roberts, E. S., and Hollenberg, P. F. (1996) Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-depre-nyl and clorgyline. Drug Metab. Dispos. 24, 669-675
51. Pai, K. S., and Ravindranath, V. (1991) Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer. In vitro studies with brain slices. Brain Res. 555, 239-244
52. Valoti, M., Fusi, F., Frosini, M., Pessina, F., Tipton, K. F., and Sgaragli, G. P. (2000) Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes. Effects of in vivo pretreatment with ethanol, phenobarbital, β-naphthoflavone, and L-deprenyl. Eur. J. Pharmacol. 391, 199-206
53. Mann, A., Miksys, S. L., Gaedigk, A., Kish, S. J., Mash, D. C, and Tyndale, R. F. (2012) The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson disease patients. Neurobiol. Aging 33, 2160-2171
54. Anandatheerthavarada, H. K., Addya, S., Dwivedi, R. S., Biswas, G., Mul-lick, J., and Avadhani, N G. (1997) Bimodal targeting of cytochrome P450s to endoplasmic reticulum and mitochondria. The concept of chimeric signals. Arch. Biochem. Biophys. 339, 136-150
55. Anandatheerthavarada, H. K., Addya, S., Mullick, J., and Avadhani, N. G. (1998) Localization of multiple forms of inducible cytochromes P450 in rat liver mitochondria. Immunological characteristics and patterns of xenobiotic substrate metabolism. Biochemistry 37, 1150-1160
56. Avadhani, N. G., Sangar, M. C, Bansal, S., and Bajpai, P. (2011) Interaction of adrenodoxin with P4501A1 and its truncated form P450MT2 through different domains. Differential modulation of enzyme activities. FEBS J. 278, 4218-4229
57. Robin, M. A., Anandatheerthavarada, H. K., Fang, J. K., Cudic, M., Otvos, L., and Avadhani, N. G. (2001) Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity. J. Biol. Chem. 276, 24680-24689
58. Anandatheerthavarada, H. K., Vijayasarathy, C, Bhagwat, S. V., Biswas, G., Mullick, J., and Avadhani, N G. (1999) Physiological role of the N-termi-nal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesis. J. Biol. Chem. 274, 6617-6625
59. Anandatheerthavarada, H. K., Amuthan, G., Biswas, G., Robin, M. A., Murali, R., Waterman, M. R., and Avadhani, N. G. (2001) Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points. EMBO J. 20, 2394-2403
60. 2-terminal truncated cytochrome P4501A1 in rat brain during chronic treatment with β-naphthoflavone. A role in the metabolism of neuroactive drugs. J. Biol. Chem. 275, 34415-34423
61. Bansal, S., Liu, C. P., Sepuri, N. B., Anandatheerthavarada, H. K., Selvaraj, V., Hoek, J., Milne, G. L., Guengerich, F. P., and Avadhani, N. G. (2010) Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J. Biol. Chem. 285, 24609-24619
62. Dong, H, Dalton, T. P., Miller, M. L., Chen, Y., Uno, S., Shi, Z., Shertzer, H. G., Bansal, S., Avadhani, N. G., and Nebert, D. W. (2009). Knock-in mouse lines expressing either mitochondrial or microsomal CYP1A1. Differing responses to dietary benzo[a]pyrene as proof of principle. Mol. Pharmacol. 75, 555-567
63. Smith, R. A., Hartley, R. C, and Murphy, M. P. (2011) Mitochondria-targeted small molecule therapeutics and probes. Antioxid. Redox Signal. 15, 3021-3038
64. Tanaka, A., Cleland, M. M., Xu, S., Narendra, D. P., Suen, D. F., Karbowski, M., and Youle, R. J. (2010) PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. J. Cell Biol. 191, 1367-1380
65. Vives-Bauza, C, Zhou, C, Huang, Y., Cui, M., de Vries, R. L., Kim, J., May, J., Tocilescu, M. A., Liu, W., Ko, H. S., Magrané, J., Moore, D. J., Dawson, V. L., Grailhe, R., Dawson, T. M., Li, C, Tieu, K., and Przedborski, S. (2010) Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. Proc. Natl. Acad. Sci. U.S.A. 107, 378-383
66. Frank, S., Gaume, B., Bergmann-Leitner, E. S., Leitner, W. W., Robert, E. G., Catez, F., Smith, C. L., and Youle, R. J. (2001) The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev. Cell 1, 515-525
67. Arnoult, D., Rismanchi, N, Grodet, A., Roberts, R. G., Seeburg, D. P., Estaquier, J., Sheng, M., and Blackstone, C. (2005) Bax/Bak-dependent release of DDP/TIMM8a promotes Drp1-mediated mitochondrial fission and mitoptosis during programmed cell death. Curr. Biol. 15, 2112-2118
68. Vila, M., and Przedborski, S. (2003) Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 365-375